nivolumab,ipilimumab
bms
[]
really agree with . our community has to strive for this. when these data are shown, we cannot accept anymore approvals based on premature endpoints and delay treatments despite benefit is obvious!! it is time to act! #esmo22 
??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.